Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $216.07

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have received a consensus recommendation of "Buy" from the fifteen ratings firms that are currently covering the company, MarketBeat reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $216.07.

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $200.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $180.00 to $250.00 in a research note on Monday, May 5th. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Royal Bank of Canada raised their price objective on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research report on Friday, May 2nd.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently modified their holdings of ASND. T. Rowe Price Investment Management Inc. lifted its position in shares of Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock valued at $375,226,000 after acquiring an additional 960,504 shares during the period. Capital International Investors lifted its position in shares of Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after acquiring an additional 753,859 shares during the period. RA Capital Management L.P. increased its stake in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $51,029,000. Finally, Vestal Point Capital LP increased its stake in shares of Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock worth $71,588,000 after purchasing an additional 270,000 shares in the last quarter.

Ascendis Pharma A/S Trading Up 0.0%

Shares of ASND traded up $0.06 during mid-day trading on Wednesday, hitting $157.60. 502,233 shares of the company's stock were exchanged, compared to its average volume of 494,382. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The firm has a market capitalization of $9.61 billion, a P/E ratio of -22.20 and a beta of 0.41. The business's 50 day moving average is $157.15 and its two-hundred day moving average is $142.36.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million. On average, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.